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A B S T R A C T
Background: ε4 allele possession is associated with an increased risk of Alzheimer’s disease. Its eﬀects earlier in
life are less well understood. Previous studies have reported both detrimental eﬀects and a lack of eﬀect on
cognition outside dementia. We used genotype based recall from the ALSPAC study to investigate whether APOE
genotype inﬂuences cognition in earlier adult life.
Methods: We invited all individuals with the rarer ε22 or ε44 genotypes and equal numbers of those with ε32,
ε33 or ε34 APOE genotypes (total n invited = 1936, ages 23–67). Participants were screened for dementia using
the Addenbrooke’s Cognitive Examination Revised (ACE-R). Participants were asked to complete a 3 h battery of
neuropsychological tests covering a range of cognitive domains. The primary outcome was performance on the
Rey Auditory Verbal Learning Test (RAVLT). Transformation of variables was used where required to permit
parametric testing. As genotypes are unlikely to be confounded unadjusted analyses were performed.
Results: 114 participants were recruited to the study (39 ε33, 27 ε34, 15 ε44, 26 ε32 & 7 ε22). ε4+ participants
had higher scores on the cognitive failures questionnaire (10 point increase, p=0.006) but no deﬁcits on ob-
jective cognitive testing. ε2 carriers had slightly better episodic memory performance (p=0.016), slightly
improved n-back accuracy and better executive functioning (trails A & B, p= 0.005).
Conclusions: It is intriguing that the ε2+ group performed better as this group have a lower risk of Alzheimer’s
disease. Most previous studies have analysed as ε4/non ε4 so may have missed this eﬀect.
1. Introduction
The human APOE gene has three alleles: ε2, ε3 and ε4. Possession of
an ε4 allele (compared to ε3) has been linked to a higher risk of de-
veloping and earlier age at onset of late onset Alzheimer’s disease (AD)
(Corder et al., 1993) with evidence of an allele dose eﬀect (Bertram,
McQueen, Mullin, Blacker, & Tanzi, 2007). One ε4 allele confers a
threefold increase in risk and possession of two ε4 alleles confers an
over tenfold increase in risk (Bertram et al., 2007). Possession of an ε2
allele has been linked with a lower risk of AD and may also slow pro-
gression of vascular cognitive impairment (Blacker, Lee, Muzikansky,
et al., 2007; Corder et al., 1994; Kim et al., 2017; Talbot et al., 1994).
Possession of an ε4 allele is neither necessary nor suﬃcient for the
development of AD and many ε4 allele carriers live to advanced ages
with no evidence of dementia (Bunce, Fratiglioni, Small,
Winblad, & Bäckman, 2004). It has been suggested that ε4 reduces the
age at onset of AD but does not inﬂuence whether someone develops it
(Meyer et al., 1998). Studies over several decades have reported that ε4
allele possession may have more of a deleterious eﬀect in women
(reviewed in (Ungar, Altmann, & Greicius, 2014)).
It has been shown in post-mortem brain studies and in PET studies
of older adults that ε4 allele possession is associated with higher levels
of amyloid plaques (Caselli, Walker, Sue, Sabbagh, & Beach, 2010;
Wirth, Villeneuve, La Joie, Marks, & Jagust, 2014). In one study this
eﬀect was seen even in middle-aged individuals (Ghebremedhin,
Schultz, Braak, & Braak, 1998). ε4 eﬀects on neuroﬁbrillary tangles are
much less consistent (Raber, Huang, & Ashford, 2004). In contrast in-
dividuals with the ε2 variant have less AD neuropathology before ex-
treme old age (Berlau, Corrada, Head, & Kawas, 2009; Ohm, Scharnagl,
Marz, & Bohl, 1999).
Most previous studies of the eﬀect of ε4 on cognition in non-de-
mented adults have included older participants. Relatively few have
studied younger people (only 8 studies with a mean age of under 50 y in
a 2017 meta-analysis) or reported the presence of the ε2 allele
(Lancaster, Tabet, & Rusted, 2017). Indeed in one study possession of ε2
was an exclusion criterion (Evans et al., 2014). A meta-analysis in 2011
found evidence of improved episodic memory in ε2 carriers from 6
studies (mean eﬀect size 0.09, 95% CI −0.05 to 0.22) (Wisdom,
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Callahan, & Hawkins, 2011). The same meta-analysis reported that the
adverse eﬀects of ε4 on cognition (in the absence of dementia) increases
with age, yet many previous studies have not adequately screened for
dementia (Wisdom et al., 2011). In particular many studies have used
the mini mental state examination (MMSE) which is much less sensitive
to the presence of early dementia (or mild cognitive impairment) than
other tests such as the Addenbrooke’s cognitive examination revised
(ACE-R) (Mioshi, Dawson, Mitchell, Arnold, & Hodges, 2006).
Although compromised by lack of phenotypic precision, a GWAS
meta-analysis which analysed a general cognitive ability score from
heterogeneous individual studies found that the eﬀect of ε4 was
minimal in middle age and increased with age (Davies et al., 2015).
Other studies have reported that the separation between ɛ4 carriers and
non-ɛ4 carriers on cognitive tests starts in the mid 50 s (Caselli et al.,
2009) and as early as 35 years old (Bunce, Anstey, Burn,
Christensen, & Easteal, 2011). The largest recent study of middle aged
adults, which used data from the Generation Scotland study, showed
detrimental eﬀects of ε4 on logical memory and processing speed.
These eﬀects appeared to be larger in those aged>60 y in a sensitivity
analysis (Marioni et al., 2016).
There remains considerable debate as to whether the changes seen
in some previous studies reﬂect genuine ε4 eﬀects in the absence of
dementia, or merely the early stages of a dementing process. The latter
is entirely possible as amyloid can be found in the brain at least 10
years before the diagnosis of a dementia (Fouquet, Besson, Gonneaud,
La Joie, & Chételat, 2014; Morris et al., 2010). Evidence of cognitive
decline has been shown 10 and 12 years before the onset of AD (Amieva
et al., 2008; Tierney, Yao, Kiss, &McDowell, 2005).
Perhaps unsurprisingly, given the known relationship of ε4 to AD
risk, most previous studies have included a measure of episodic
memory. The cognitive domains of attention, executive function and
visuospatial function have been much less well studied (Wisdom et al.,
2011). In the 2011 meta-analysis by Wisdom et al. the mean eﬀect size
for ε44 homozygotes on episodic memory was−0.18 (95% CI−0.34 to
−0.02) and for ε34 participants it was −0.04 (95%CI −0.09 to 0.01).
There was also evidence of small ε4 eﬀects on executive functioning
(eﬀect size −0.06, 95% CI −0.12 to −0.04) and perceptual speed
(eﬀect size −0.07, 95% CI −0.13 to −0.01) (Wisdom et al., 2011).
Although episodic memory is the major cognitive process aﬀected early
in LOAD, it is not the only process aﬀected early in the disease process
(Backman, Jones, Berger, Laukka, & Small, 2005). Poor working
memory performance has been reported as one of the earliest deﬁcits
seen in Alzheimer's disease (McKhann et al., 1984). The current study
builds on previous work by including younger participants, including a
relatively large number of ε2+ participants, rigorously screening for
dementia (to exclude this as a cause of any diﬀerences observed) and by
testing multiple domains of cognition.
Whilst some individual studies have suggested that there is a posi-
tive pleiotropic eﬀect of ε4 in younger adults (e.g. Hubacek et al., 2001)
a meta-analysis found no evidence of such an eﬀect (Ihle,
Bunce, & Kliegel, 2012). The authors suggested that this may have been
because several of the studies used less diﬃcult tasks that may have
failed to pick up subtle eﬀects.
We wished to study the eﬀects of APOE genotype on cognition in-
dependent of dementia. We hypothesised that cognitive function is re-
duced in young to middle aged adults without dementia from the
ALSPAC study with an ε4 allele compared to those without.
Recall by genotype is an eﬃcient study design which allows causal
inference, precision phenotyping and maximises statistical power
(Ware, Timpson, Davey Smith, &Munafò, 2014). It involves selecting a
deﬁned number of participants with each genotype at random from an
existing study with genetic data. These participants are then invited to
take part in the recall study. Dense phenotyping can be performed in
the recall study which would be impracticable to perform on the whole
study cohort.
2. Methods and materials
2.1. Ethics
Ethical approval for this study and approval for substantial
amendments was provided by the ALSPAC ethics and law committee
(study ref E201109). Both researchers and participants were blind to
APOE genotype status. All participants gave written informed consent
to take part in this study following assessment of their capacity to do so
by a Psychiatrist (LIS).
2.2. The Avon longitudinal study of parents and children
The Avon Longitudinal Study of Parents and Children (ALSPAC) as
described previously in detail is a prospective study which was estab-
lished in 1991 (Boyd et al., 2012; Fraser et al., 2012). Initially 14,541
women were enrolled, resulting in 14,062 live births and 13,988 chil-
dren alive at one year. At age 7/8 further eligible children were added
to the sample, giving a total sample size of 15,247 eligible pregnancies
and 14,775 live births. Data were collected from self-report ques-
tionnaires, teacher report questionnaires, medical, educational and
other records, birth registries, and hands on assessment. Detailed in-
formation has been collected since birth via questionnaires and at
regular clinics. The study website contains details of all the available
data through a fully searchable data dictionary (http://www.bris.ac.
uk/alspac/researchers/data-access/data-dictionary/).
2.3. APOE genotyping
Genotyping of all study participants for APOE was undertaken by
integrated single label liquid phase assay as previously described
(Abdollahi et al., 2006). DNA samples were available in 2009 for 7091
children, 63% of the 11343 ALSPAC children with potential DNA
samples available. In total 95% of these samples were genotyped
(Taylor et al., 2011). After siblings and children of known non-white
ethnicity were excluded there was genotype data for 5995 children.
DNA samples were available in 2010 for 9763 mothers: 83.6% of the
11,679 mothers with potential DNA samples available. In total 87.9% of
these samples were able to be genotyped. There was no strong evidence
of a sex diﬀerence in genotype distribution or of a deviation from Hardy
Weinberg Equilibrium for either the mothers or young people
(p > 0.05).
2.4. Recall by genotype
Inclusion criteria for this study were that participants had pre-
viously taken part in the ALSPAC study and that they had a known
APOE genotype. Exclusion criteria were; drop out from ALSPAC;
living>50 miles away; already taking part in an ALSPAC sub-study;
very poor command of English; lack of capacity to consent; and de-
mentia.
Recruitment to the study is summarised in Fig. 1. The planned
strategy was to identify whether a per-genotype diﬀerence existed be-
tween the homozygotes and then to ascertain whether there was an
allele dose eﬀect by inviting heterozygotes in a second wave. Due to a
very poor response rate to the ﬁrst wave the invitations to the second
case selection were sent earlier than planned.
Participants in each batch of invitations were chosen at random
from the case selection. They were sent an initial invitation, a reminder
postcard after 3 weeks (if they had not replied) and if they had still not
replied were contacted by telephone. All participants were reminded
the day prior to their appointment. In order to maintain double blinding
as to participant genotype, all invitation letters, case selections, tele-
phone calls and participant contact other than the study visit were
carried out by ALSPAC staﬀ and not by the researchers.
Despite all of these measures the ﬁnal response rate (either positive
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or negative) was only 16%. Participants and the rest of the ALSPAC
study population were compared (see Supplementary Table 1).
2.5. Co-variates
Information was available on a range of possible confounders in-
cluding IQ, blood pressure, serum cholesterol, past medical history,
mood rating scales and demographic variables.
2.6. The study visit
The study visit lasted for up to 3 h. Participants were screened for
dementia using the ACE-R, which incorporates the MMSE (Mioshi et al.,
2006). Information was gathered on head injuries, history of mental
illness, current medication, caﬀeine consumption, alcohol intake, illicit
drug use and family history of dementia. All young people completed
the moods and feelings questionnaire (Angold et al., 1995). All mothers
completed the Edinburgh Postnatal Depression Scale (EPDS) (Cox,
Holden, & Sagovsky, 1987) and the Crown-Crisp Inventory
(Crown & Crisp, 1966). These questionnaires were chosen to allow
comparison with data previously collected by ALSPAC. All participants
completed the Depression, anxiety and stress scale (DASS) and the
Cognitive Failures Questionnaire (CFQ) (Broadbent, Cooper,
FitzGerald, & Parkes, 1982; Lovibond & Lovibond, 1995a;
Lovibond & Lovibond, 1995b). The DASS may be downloaded from
www.psy.unsw.edu.au/dass/. Full scale IQ was measured using the
Wechsler abbreviated scale of intelligence (WASI) (Wechsler, 2011).
The neuropsychological battery included the Rey Auditory Verbal
Learning Test (RAVLT), bespoke episodic list learning and paired as-
sociative list learning tasks, a Stroop test, digit span, n-back, verbal
ﬂuency (FAS and animals), the Rey Osterrieth complex ﬁgure, trails
A & B, simple & choice reaction time and a bespoke visual motion task
(Borkowski, Benton, & Spreen, 1967; Kirchner, 1958; Rey, 1941; Rey,
1964; Rm, 1955; Spreen & Strauss, 1998; Stroop, 1935; War
Department Adjutant General’s Oﬃce, 1944; Wechsler, 1997) Tests
were carried out in a standard order and breaks were oﬀered at two
regular points. No feedback was oﬀered to participants on how they had
performed on the tests. The researcher was present during all tests.
Participants were requested to refrain from smoking and to drink only
one cup of their normal caﬀeinated beverage the morning of the study
visit. This was to avoid the known eﬀects of caﬀeine on performance in
such tests (Ker, Edwards, Felix, Blackhall, & Roberts, 2010).
Participants were read standardised instructions for each task im-
mediately before completing them. In the simple reaction time task
participants were asked to press a response key as soon as they saw the
stimulus. The interval between trials was a random value between
1000ms and 1500ms. In the choice reaction task participants were
asked to press one key if the stimulus was red and a diﬀerent key if it
was green. The interval between trials was a random value between
1000ms and 2000ms.
In the Stroop task participants were requested to push one of three
keys each time a stimulus was displayed, to indicate if the colour of the
word was red, green or blue. Congruent, incongruent and neutral sti-
muli (XXX of the same length as the other words) were displayed until
the participant responded. The interval between trials was a random
value between 1000ms and 1500ms. There were up to 36 trials of each
condition.
For the n-back task participants were asked to press the space bar if
they recognised a letter as being the same as n letters back. The re-
sponse key was the same in all conditions. Each letter was displayed for
2 s with a 1 s interval between letters.
During the visual motion task participants were asked to push; one
key if the stimulus was going in the same direction as the other objects;
and a diﬀerent key if the stimulus was going in a diﬀerent direction to
the other objects. There were 3 diﬀerent speeds that the stimulus
moved at, with 30 trials at each speed. Each trial moved to the next
when the participant pressed a key.
2.7. Statistical analysis
All analyses were carried out in STATA v13. There was no evidence
to support an association of any demographic variables or potential
confounders with APOE genotype (Table 1). Given that participants
with each genotype were selected at random and that genotypes are
unlikely to be confounded in any case, it was decided not to include any
co-variates in the analysis.
A power calculation estimated a total n of 350 i.e. 70 in each gen-
otype group to ensure 80% power with an α of 0.05. It soon became
apparent that this was not going to be possible so numbers were max-
imised wherever possible. To maximise study power an analysis
strategy of combining ε32 and ε22 to form an ε2+ group and com-
bining ε34 and ε44 to form an ε4+ group was used with ε33 as the
reference group.
Transformation of variables was used where necessary to permit
parametric testing. Where parametric testing was possible the data was
initially analysed using ANOVA and subsequently by linear regression.
Non-parametric testing was performed using the Kruskal-Wallis and
Dunn’s post hoc tests. Eﬀect sizes were calculated, where possible, using
the post hoc estate size command in Stata after ANOVAs.
For the N-back data multi-level regression was used, as described
previously (Sinclair, Button, Munafò, Day, & Lewis, 2015). Un-
fortunately reaction times were not available for target/non-target so
the reaction time data was only re-shaped according to the diﬃculty
level. It was not possible to use multilevel regression for accuracy in the
visual motion task as the data had a truncated normal distribution, but
it was possible to use a repeated measures ANOVA.
Fig. 1. The ﬂow of potential participants through the study.
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For the simple reaction time all unfeasibly long (> 1000ms) or
short (< 120ms) reaction times were excluded before calculation of
mean and median reaction times. A further corrected (C-mean) mean
reaction time was calculated by excluding all reaction times> 2SD
away from the sub-mean. The C-mean was then used in analyses. For
the choice reaction time task the same procedure was followed, except
that the upper limit for excluding unfeasibly long reaction times was
raised to 2000ms. The diﬀerence between the choice C-mean and
simple C-mean was calculated and used in the analysis as this is a purer
measure of choice than the choice reaction time alone.
We made an a priori decision to exclude individuals with an ε42
genotype from analyses as this group mixes the high and lowest risk
alleles. This is standard practice in APOE research (e.g. Alexander et al.,
2007) We also made an a priori decision to exclude those who
scored< 82 on the ACE-R as this has optimal sensitivity for dementia
(Mioshi et al., 2006).
3. Results
3.1. Demographics
The study population diﬀered by APOE genotype from those in the
case selection who did not take part (see Table 1). In particular
homozygotes for rare alleles were more likely to participate. The cause
for this is unknown. Although homozygotes were invited ﬁrst and then
heterozygotes in the second wave of invitations the case selection was
performed at random (other than for homozygotes for rare genotypes
who were all invited to participate) and participants were then invited
in a random order. There was no diﬀerence in the rate of family history
of dementia between the groups. The expected eﬀect of APOE genotype
on serum LDL cholesterol was observed (Zacho et al., 2008). The age
range of those who took part was 23–24 (young people) and 42–67
(mothers). There were 33 individuals with an ε2+ genotype with an
age range of 23–24 (young people) and 43–67 (mothers). There were 39
individuals with an ε33 genotype whose ages ranged from 23 to 24
(young people) and 42 to 62 (mothers). Finally there were 42 in-
dividuals with an ε4+ genotype, with ages ranging from 23 to 24
(young people) and 42 to 62 (mothers).
Table 1
Characteristics of the study population.
Variable ε2+ ε33 ε4+ Statistical evidence (ANOVA or Mann Whitney)
Mean SD Mean SD Mean SD
Within case selection
Took part in study 33 39 42 ⩽p 0.0001*
Did not take part in study 721 661 788
Mean age of mothers at visit (yrs) 51.424 4.867 50.282 3.993 51.143 4.459 p = 0.513
Gender
Male 20 15 20 Χ2 = 3.521
Female 13 24 22 p = 0.172
Young Person (YP) 22 21 23 Χ2 = 1.473
Mother 11 18 19 p = 0.479
IQ 114.333 7.292 112.921 11.741 113.488 10.107 Χ2 = 0.208
p = 0.901
Mini Mental State Examination (MMSE) score 29.788 0.415 29.553 0.86 29.667 0.612 Χ2 = 0.732
p = 0.693
Addenbrooke’s Cognitive Examination (ACE-R) score 93.909 3.076 93.676 4.137 93.167 3.963 Χ2 = 0.460
p = 0.795
Positive family history of dementia (%) 0.394 0.297 0.415 Χ2 = 1.488
p= 0.475
History of a signiﬁcant head injury (%) 0.152 0.263 0.195 Χ2 = 0.217
p = 0.897
No. of participants who use cannabis regularly 3.500 0.707 0 0 0.750 1.5 N/A
No. of participants who use stimulants regularly 0.500 0.707 0 0 0 0 N/A
No. of cups of caﬀeine containing drink usually consumes per day 2.604 2.04 3.459 2.34 3.839 3.144 Χ2 = 3.034
p= 0.219
No. of cups of caﬀeine containing drink consumed that day 0.613 0.715 0.73 0.871 0.902 1.934 Χ2 = 0.046
p= 0.977
Units of alcohol per week 10.348 12.519 9.456 10.997 7.488 8.092 Χ2 = 0.708
p= 0.702
Personal history of epilepsy 0.061 0.026 0.024 Χ2 = 0.895
p = 0.639
History of anxiety disorder 0.121 0.237 0.190 Χ2 = 1.445
p = 0.486
History of depression 0.121 0.184 0.262 Χ2 = 2.418
p= 0.298
History of psychotic disorder 0 0 0 N/A
Crown-Crisp total score 25.697 36.987 35.526 38.2 32.667 36.701 Χ2 = 3.006
p= 0.222
Cognitive Failures Questionnaire Score 30.121 13.944 32.263 11.95 38.929 15.371 Χ2 = 6.051
p = 0.049*
Last available cholesterol (mothers) mmol/L 4.813 0.9 5.202 0.913 5.049 0.536 p<0.001*
Depression, Anxiety and Stress Scale (DASS) total score 9.424 9.572 7.553 6.769 17.214 16.389 Χ2 = 7.487
p = 0.024*
Edinburgh Postnatal Depression Scale (EPDS) total score 4.212 6.143 5.789 6.338 5.69 6.426 Χ2 = 1.022
p = 0.600
Moods & Feelings total score 3.061 2.85 2.421 2.937 3.524 4.49 Χ2 = 0.375
p = 0.829
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3.2. Test battery results
There was little evidence of a per genotype diﬀerence in perfor-
mance on the reaction time, digits forwards/backwards task, the Rey-
Oesterrieth complex ﬁgure task or the Stroop test (see Table 2). Al-
though the initial ANOVA was suggestive of a per genotype diﬀerence
in phonemic ﬂuency (p = 0.047) no evidence of a diﬀerence was seen
in a subsequent linear regression. There was no evidence of a per
genotype diﬀerence in category ﬂuency (p = 0.647).
3.3. Episodic memory
In the main analysis there was no evidence of a per genotype dif-
ference in performance at the long delay timepoint in the RAVLT (see
Fig. 2B). As shown in Fig. 2A the ε2+ group remembered slightly more
words in the ﬁrst 5 trials of the RAVLT (5.1 more words, Χ2 = 6.663, p
= 0.036) In addition there was evidence from both the Kruskal-Wallis
and Dunn’s tests that ε2 carriers performed better on the episodic list
learning task (1.6 more words, Χ2 = 6.842, p = 0.016) (see Fig. 3).
This was an immediate recall task. There was no evidence of a per-
genotype diﬀerence in the paired associative learning task.
3.4. Executive functioning
There was reasonable strength evidence that those with an ε2 allele
were faster (i.e. performed better) in the trails A & B test (Χ2 = 11.704,
p = 0.003, see Fig. 4). The Kruskal-Wallis and Dunn’s post hoc test
suggested that there was a diﬀerence between the ε2+ group and the
ε33 (p = 0.005) and the ε4+ group (p< 0.001). This should be in-
terpreted with caution.
3.5. Working memory
As would be expected the participants had almost perfect accuracy
on the 1-back task (see Table 3). Accuracy was lower for the 2-back and
much lower for the 3-back, as anticipated. Neither the accuracy vari-
able nor d’ were normally distributed (truncated normal distribution
with an upper limit of 1.0) and it was not possible to transform them. It
was not possible to calculate d’.
The regression was therefore performed with bootstrapping as this
method does not require a normal distribution. The residuals from this
regression were normally distributed. The results were unchanged with
bootstrapping. There appeared to be improved accuracy (3.6% increase,
β = 0.036 (95% CI = 0.003–0.069), p = 0.034) in the ε22 group,
although the overall likelihood test for an eﬀect of APOE suggested that
there was no eﬀect (p = 0.091, see Table 3). The overall r2 was 0.473.
There was no evidence that APOE genotype inﬂuenced reaction time
to target in the 2- or 3-back n-back task (p = 0.888, see Table 3).
Table 2
Results from the neuropsychological test battery. Χ2 refers to statistical evidence from the Kruskal Wallis test.
Variable ε2+ ε33 ε4+ Statistical evidence (ANOVA or Kruskal Wallis)
Mean SD Mean SD Mean SD
Digits forwards 6.061 1.029 5.925 1.185 5.907 1.25 p = 0.835
Eﬀect size = 0.003
Digits backwards 4.576 1.437 4.3 1.381 4.186 1.367 p = 0.496
Eﬀect size = 0.013
RAVLT trials I-V recall (errors) 1.636 2.133 1.425 2.024 1.419 1.918 Χ2 = 1.205
p = 0.547
RAVLT trials I-V recall (repetitions) 15.424 12.281 9.05 10.583 13.791 15.239 Χ2 = 4.650
p = 0.098
RAVLT trials I-V recall (total) 57.848 7.484 52.7 10.118 53.884 7.582 Χ2 = 6.663
p = 0.036*
RAVLT trial VII delayed recall (errors) 11.969 2.901 10.75 3.095 11.214 2.968 Χ2 = 0.523
p = 0.770
RAVLT trial VII delayed recall (total) 11.969 2.901 10.75 3.095 11.214 2.968 Χ2 = 2.980
p = 0.225
Verbal ﬂuency (FAS) total no. words 43.697 8.432 41.25 11.047 41.186 11.065 p = 0.567
Eﬀect size = 0.010
Category ﬂuency (animals) 23.636 3.959 21.85 5.323 23.093 4.83 p = 0.355
Eﬀect size = 0.018
Paired associative learning (errors) 1.667 1.931 1.725 1.961 2.465 2.693 Χ2 = 2.907
p = 0.234
Paired associative learning (total) 51.242 7.08 45.7 13.921 46.651 9.768 Χ2 = 4.722
p = 0.094
Rey-Osterrieth ﬁgure delayed recall 22.788 4.697 20.075 7.604 21.093 6.045 p = 0.317
Eﬀect size = 0.029
Rey-Osterrieth ﬁgure immediate recall 23.561 5.275 19.738 8.252 21.244 6.073 p = 0.104
Eﬀect size = 0.040
Trails B – Trails A (secs) 20.595 9.636 36.745 41.301 33.835 23.521 Χ2 = 11.704
p = 0.003*
Episodic list learning total recalled 11.697 2.687 10.075 3.214 10 3.471 Χ2 = 6.842
p = 0.033*
Episodic list learning errors 0.424 0.792 0.475 0.816 0.31 0.643 Χ2 = 0.781
p = 0.677
C-mean simple reaction time (ms) 292.049 38.829 284.925 34.884 289.379 29.281 Χ2 = 0.839
p = 0.657
C-mean choice reaction time (ms) 438.109 59.592 440.356 60.409 446.225 53.149 p = 0.778
Eﬀect size = 0.004
Choice RT error rate 0.036 0.021 0.041 0.029 0.047 0.042 Χ2 = 1.990
p = 0.370
Stroop interference eﬀect (ms) 91.878 95.07 124.454 94.421 109.775 84.805 p = 0.324
Eﬀect size = 0.020
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3.6. Visual motion task
The motion task had 3 levels of speed and 2 levels for target i.e.
present/absent. One participant was excluded because they had a large
number of unfeasibly fast reaction times (< 120ms) and their accuracy
was at chance level. When calculating the reaction time all unfeasibly
short (< 120ms) reaction times were excluded before calculation of
mean and median reaction times. A further corrected (C-mean) mean
reaction time was calculated by excluding all reaction times> 2SD
away from the sub-mean. Only 1 trial from one participant was ex-
cluded because of a reaction time<120ms.
Multi-level regression of accuracy was not possible because a
normal distribution could not be obtained. The analysis proceeded
using d’ as this takes account of both accuracy to target and false
alarms. The discriminability index (better known as d’) is a measure of
signal strength that takes account of signal and “noise”. To prevent a
false alarm rate of 0 (and thus an inﬁnitely large d’) where the false
alarm rate was zero it was adjusted to be 1/N where N was the number
of valid trials for that participant.
Because the within subject co-variance of the d’ data structure was
compound symmetric it was possible to use a repeated measures
ANOVA. There was no evidence that APOE genotype had an eﬀect on d’
(see Table 4 and supplementary Tables 4 and 5).
Multilevel regression for reaction time was possible by inverse
transformation of reaction time (see Table 4 and supplementary
Table 6). There was no evidence of an APOE eﬀect on reaction time.
3.7. Self-reported cognitive diﬃculties
There was evidence from the cognitive failures questionnaire (CFQ)
that self-reported cognition was worse in those with an ε4 allele (Χ2 =
6.051, p = 0.006, see Fig. 5A). Those with an ε4 allele also scored
somewhat higher on the depression anxiety and stress scale (DASS). The
overall Kruskal-Wallis test and the Dunn’s post-hoc test (see Fig. 5B)
suggested that those with an ε4 allele scored higher on this scale than
either of the other two groups (increase = 9.7 points, overall p value =
0.024, Χ2 = 7.487, comparison to ε33 group p = 0.009)
3.8. Eﬀect of age group
The dichotomised age groups in this study allowed us to examine
diﬀerences in observed APOE genotype eﬀects between young people
and middle aged women. Unfortunately low numbers precluded sta-
tistical analysis, but the data are presented graphically in
Supplementary Figs. 1–7. It would seem that the ε2+ positive eﬀect on
episodic memory was seen predominantly in the young people and the
ε2+ eﬀect in the trails A & B test was seen in both age groups. It ap-
pears that ε4 had slightly more eﬀect on DASS scores in the mothers,
which is surprising as there were no per genotype eﬀects on either the
Crown-Crisp or the EPDS which overlap somewhat with the DASS.
Fig. 2. Results from the RAVLT. There was evidence that the ε2+ group remembered
more words in trials I-V (A) but no statistical evidence to support a between group dif-
ference at the long delay time point (B). The standard deviations for each group are
shown in the error bars. A post hoc Dunn’s test suggested that the ε2+ group remembered
more words than either the ε33 group (p = 0.011) or the ε4+ group (p = 0.012). *
denotes p<0.05.
Fig. 3. Episodic list learning. The standard deviations for each group are shown in the
error bars. There was evidence from a post-hoc Dunn’s test that the ε2+ group performed
better than the ε33 (p = 0.016) group and the e4+ group (p = 0.007). * denotes
p<0.05.
Fig. 4. The results shown are the time taken to complete the trails B task minus the time
taken to complete the trails A task. Standard deviations for each group are shown in the
error bars. There was evidence from a post-hoc Dunn’s test that the ε2+ group performed
better than the ε33 (p = 0.005) group and the ε4+ group (p<0.001). * denotes p< 0.05
and ** denotes p< 0.01.
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Finally it seems that the higher scores on the CFQ for individuals with
an ε4+ genotype was driven by the young people. Due to low numbers
these ﬁndings are speculative and impossible to prove.
4. Discussion
We found evidence to suggest that ε4 allele possession is associated
with more self-reported cognitive failures, but minimal objective dif-
ference in cognitive performance compared to the reference ε33 group.
We also found that possession of an ε2 allele is associated with slightly
better episodic memory performance, slightly improved accuracy on
the n-back task and better executive functioning (as measured by trails
A & B) than the reference ε33 group. There was no evidence of a per
genotype diﬀerence in reaction time, attention, verbal ﬂuency or
working memory. Eﬀect sizes, where it was possible to calculate them,
were very low. It is intriguing that the ε2 carriers, who have an up to
50% reduction in the risk of AD should demonstrate advantage in
episodic memory and executive functioning tasks as these are cognitive
domains aﬀected early in the development of AD. Although Wisdom
et al. found a beneﬁcial eﬀect of ε2 on episodic memory, the very large
generation Scotland study (which had ten times the number of ε2 car-
riers) found no eﬀect of ε2 on any cognitive domain examined (Marioni
et al., 2016; Wisdom et al., 2011).
In a 2011 meta-analysis Wisdom et al. found that ε2 carriers per-
formed better than ε4 carriers in episodic memory tests (eﬀect size d =
0.09, p<0.05) but they did not ﬁnd any statistical evidence of dif-
ference from the reference ε33 group. This was based on 6 studies and a
total n of 270 ε2 carriers (Wisdom et al., 2011). This ﬁnding is con-
sistent with previous research. For example, the Religious Orders study
found that episodic memory performance in ε2 carriers did not decrease
with age, unlike ε33 and ε4 carriers, although at least 15% of its cohort
developed AD during the ≤8 y follow-up period (Wilson, Bienias,
Berry-Kravis, Evans, & Bennett, 2002). A similar Finnish community
based study with a 3 y follow-up had similar results (Helkala et al.,
1996). In a secondary analysis of data from an existing longitudinal
study aimed at examining the eﬀect of cardiovascular risk factors Blair
et al. demonstrated that individuals with an ε2 allele had the least
cognitive decline over a 6 y period (Blair et al., 2005). This was a large
study, with mixed ethnicity and a mean participant age of 55. Its main
weaknesses were a loss to follow-up and a limited test battery. Con-
versely the HALCYON study, a combination of ageing cohorts, found no
meta-analytic evidence of an ε2 eﬀect on episodic memory or verbal
ﬂuency, although this was largely based on cross-sectional measures
(Alfred et al., 2014). The majority of participants came from studies
with a mean age in the mid 50 s. Given that many previous studies have
analysed their results as ε4+ vs. ε4− it is possible that if ε2 does have a
beneﬁcial eﬀect on cognition then including them in the ε4− (control)
group may have possibly inﬂated ﬁndings that ε4 allele possession has a
detrimental eﬀect on cognition.
A meta-analysis in 2011 found a small eﬀect of ε4 on episodic
memory in adults without dementia, but gave the caveat that many
studies had not adequately screened for dementia. Most of the studies
had included mainly older adults. More recent studies have also found
an eﬀect of APOE genotype on episodic memory in later adult life, for
example the limited GWAS by Andrews et al. (mean cohort age 62 y).
(Andrews, Das, Cherbuin, Anstey, & Easteal, 2016) A recent meta-ana-
lysis of the eﬀects of APOE genotype on cognition in mid life reported
no per genotype eﬀect (Lancaster et al., 2017). Only 8 studies with a
mean participant age of less than 50 y were included.
Several studies have reported that subjective memory complaints in
ε4 carriers aged over 60 are associated with greater decline in episodic
memory (Dang, 2017; Dik et al., 2001; Samieri et al., 2014). Caselli
et al. found an increased rate of subjective memory complaints in ε4
carriers in their 60 s and older (Caselli et al., 2014). Very recent work
Table 3
Results from the n-back task at levels 1, 2 and 3 back.
ε2+ ε33 ε4+
Accuracy Co-eﬃcient P-value Co-eﬃcient P-value Co-eﬃcient P-value
Multi-level regression 0.036 (0.003–0.069) 0.034* Reference group 0.008 (−0.23 to 0.040) 0.590
LR test for overall eﬀect p = 0.091
Reaction time Co-eﬃcient P-value Co-eﬃcient P-value Co-eﬃcient P-value
Statistical evidence from multi-level regression −0.001 (−0.111 to 0.110) 0.987 Reference group −0.021 (−0.125 to 0.083) 0.694
LR test for overall eﬀect p = 0.888
Table 4
C mean reaction times and accuracy rates for the diﬀerent conditions in the visual motion task. *denotes p< 0.05.
ε2+ ε33 ε4+
Mean SD Mean SD Mean SD
Accuracy Target absent Fast 0.989 0.02 0.945 0.108 0.974 0.033
Medium 0.98 0.029 0.961 0.078 0.981 0.029
Slow 0.983 0.027 0.952 0.097 0.977 0.040
Target present Fast 0.954 0.054 0.929 0.100 0.940 0.068
Medium 0.939 0.055 0.921 0.107 0.930 0.085
Slow 0.939 0.066 0.943 0.085 0.946 0.091
Repeated measures ANOVA APOE genotype p = 0.588
Interaction between APOE genotype and
level
p = 0.027
C mean reaction time
(msec)
Target absent Fast 1235.67 756.354 1072.34 820.401 1065.691 411.334
Medium 1351.498 1173.153 1065.149 781.691 1079.731 456.079
Slow 1371.326 1114.924 1108.585 879.918 1089.68 483.82
Target present Fast 819.296 301.045 740.199 324.114 750.257 252.855
Medium 828.271 316.083 747.454 258.899 783.043 264.319
Slow 993.369 488.757 847.204 316.613 868.535 306.196
Statistical evidence from multi-level
regression
Co-eﬃcient P-value Co-eﬃcient P-value Co-eﬃcient P-value
−0.014 (−0.30 to
0.002)
0.106 Reference group −0.007 (−0.023 to
0.008)
0.354
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from the Australian Womens Healthy Ageing project (age of partici-
pants mid 64–77) found that whilst ε4 carriers were not more likely to
report subjective memory complaints in response to a single question
those that did had more decline in their episodic memory at 2 year
follow up (Dang, 2017). Several of these individuals subsequently de-
veloped mild cognitive impairment. It is important to note though that
there is no consistent relationship between subjective memory com-
plaints and objective decline (Lenehan, Klekociuk, & Summers, 2012).
In our study it appears that the increase in subjective memory com-
plaints was also seen in the young people, which runs counter to the
suggestion that subjective memory complaints are an early marker of
cognitive decline in ε4+ individuals.
There are a number of possible biological explanations for the dif-
ferences in ε2 carriers. The E2 protein is more abundant than the E4,
possibly because it is more resistant to degradation (Conejero-Goldberg
et al., 2014). It has reduced aﬃnity for LDL receptors and binds more
strongly to Aβ than other ApoE isoforms, which may lead to more ef-
ﬁcient clearance of Aβ from cerebral blood vessels (Conejero-Goldberg
et al., 2014; Suri, Heise, Trachtenberg, &Mackay, 2013). Recent work
by Minett et al. suggests that the ε2 and ε4 alleles may have opposite
eﬀects on microglial activation (Minett et al., 2016). It has also recently
been demonstrated that the E2 isoform of ApoE increased synaptic
phagocytosis by astrocytes (with possible evidence of fewer senescent
synapses (Chung et al., 2016). It has been shown in post-mortem brain
studies and in PET studies of older adults that ε4 allele possession is
associated with a higher amyloid plaque load (Caselli et al., 2010;
Wirth et al., 2014). In one study this eﬀect was seen even in middle-
aged individuals (Ghebremedhin et al., 1998). ε4 eﬀects on neuroﬁ-
brillary tangles are much less consistent (Raber et al., 2004). Cumula-
tively this cell biological and neuropathological evidence goes some
way towards explaining the opposing eﬀects on the risk of AD seen with
the ε2 and ε4 genotypes.
Strengths of this study include adequate screening for dementia,
examination of a range of cognitive functions and prospective in-
formation on possible confounders. Eleven individuals in this study
scored between 82 and 88 on the ACE-R and ten of them were young
people. The mother who scored in this range had a borderline low IQ.
Educational level is known to aﬀect performance on the ACE-R
(Amaral-Carvalho & Caramelli, 2012; García-Caballero et al., 2006;
Strydom&Hassiotis, 2003). All of these individuals had an MMSE score
of 28 (2 young people) or higher. It is extremely unlikely that an in-
dividual in their 20 s would suﬀer with dementia. We can therefore be
conﬁdent that no individuals with dementia were included in this
study. There were more female than male participants, principally due
to the study design. It is possible that ε4 eﬀects on cognition might be
more pronounced in women, but this beneﬁt of our study design was
almost certainly oﬀset by poor recruitment (Ungar et al., 2014).
The main weakness of this study was poor recruitment. Recall by
genotype is an eﬃcient study design which maximises statistical power
(Ware et al., 2014). One drawback is that if recruitment is a problem
then it is an inﬂexible design. Despite strenuous eﬀorts to improve re-
cruitment we were unable to recruit further participants. Participants in
this study were better educated (mothers), more likely to come from a
family that owned its own home and had higher IQs (young people)
than the rest of the ALSPAC cohort. The phenomenon of diﬀerential loss
to follow-up in longitudinal cohort studies is well known and it is the
most likely explanation for this ﬁnding. It does however limit the
generalisability of our ﬁndings. There was little evidence of a diﬀer-
ential loss to follow-up by APOE genotype as the genotypes of all re-
maining available participants were in Hardy Weinberg Equilibrium (p
= 0.016).
In conclusion this study used recall by genotype to study individuals
with the full range of APOE genotypes. We studied younger individuals
than most previous studies and used a wider range of cognitive tests.
We did not ﬁnd any eﬀect of ε4 allele possession on objective cognitive
test performance in young to middle aged adults, but they scored higher
on the cognitive failures questionnaire (although this seemed to be
more prominent in the younger age group). Our ﬁndings support the
existing literature which suggests that objective ε4 eﬀects do not de-
velop until later adult life and may reﬂect the earlier onset of AD seen in
this genotype group. In addition we found evidence to suggest that ε2
carriers (who have a lower risk of AD) may have mildly superior per-
formance in executive functioning, working memory and episodic
memory tasks, domains known to be aﬀected early in the AD disease
process.
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